Primmune Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Jlabs 3210 San Diego, San Diego, Califor...Phone Number
(858) 205-2281Website
www.primmunerx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Primmune Therapeutics
Primmune Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, USA, focused on developing orally administered small-molecule immunotherapies that harness innate immunity to improve cancer and viral disease treatment. Its lead investigational candidate, PRTX007, is designed to activate key immune pathways without triggering broad inflammatory responses, aiming to enhance antitumor immunity and complement existing therapies while advancing through clinical studies.Explore more
Primmune Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Primmune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Primmune Therapeutics
Primmune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Primmune Therapeutics had a recent Job posting/layoffs
Check out if Primmune Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Primmune Therapeutics has new funding data
Product Launch: Get notified when Primmune Therapeutics launches new products
Check if Primmune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Primmune Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Primmune Therapeutics
Find 2 more new buyers
Compare Similar Companies to Primmune Therapeutics
Compare insights from companies similar to Primmune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Primmune Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Primmune Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Primmune Therapeutics.
Primmune Therapeutics financials insights
Gather financial insights about Primmune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$7M
2021
Series A
$31.4M
2026
Series B
$23.3M
Primmune Therapeutics Tech Stack
A closer look at the technologies used by Primmune Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Executive Move
Board of Directors
Primmune Therapeutics News & Media
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growthPrimmune Therapeutics Announces Additional Close of Series B Financing
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital. This close brings the total Series B raise to $23.3 million. These funds will be used to support the further clinical development of PRTX007, a novel orallyPrimmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction ...
SAN DIEGO--(BUSINESS WIRE)--Mar 20, 2024--Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever
SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics announces the receipt of a $22.5 million grant from the Defense Threat Reduction Agency to develop a treatment for Lassa fever.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Primmune Therapeutics
Sign Up For FreeTo access detailed company insights
Primmune Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, USA, focused on developing orally administered small-molecule immunotherapies that harness innate immunity to improve cancer and viral disease treatment. Its lead investigational candidate, PRTX007, is designed to activate key immune pathways without trigger... Read More
